EMA Authorised: Komboglyze (metformin hydrochloride;saxagliptin hydrochloride) — AstraZeneca AB

View source ↗

Summary

EMA authorised Komboglyze, a fixed-dose combination of metformin hydrochloride and saxagliptin hydrochloride for type 2 diabetes mellitus, marking a new marketi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Komboglyze (metformin hydrochloride; saxagliptin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 08/05/2025